3Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med ,2007 ,357 (26) : 2666-2676.
4Meriggin F, Abeni C ,Di Biasi B ,et al. The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment [J].Rev Recent Clin Trials,2009, 4(3):163- 167.
5Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer:Clinical expe- rience with anti-angiogenic agents, focusing on bevacizunmb [J]. Eur J Cancer,2008,44(7) :912-920.
6Miller KD, Chap LI, Holmes FA, et al. Randomized phase ~I trial of capecitabine compared with bevaeizumab plus capecit- abine in patients with previously treated metastatic breast canc- er[J]. J Clin Oncel,2005 ,23( 4 ) :792-799.
7Bmfsky AM, Hurvitz S, Perez E,et al. RIBBON-2: a random- ized, double-blind, placebo-controlled, phase ~I trial evalua- ting the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[ J ]. J Clin Oncol, 2011, 29(32) : 4286-4293.
8Zhu XL, Wu SH, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis [J].Am J Kidney D/s, 2007, 49(2) : 186-193.
9Advani A, Connelly KA, Advani SL, et al. Role of the eNOS- NO system in regulating the antiproteinuric effects of VEGF re- ceptor 2 inhibition in diabetes [ J ]. Biomed Res Int, 2013, 2013:201475.
10Mourad JJ,des Guetz G, Debbabi H,et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation [ J ]. Ann Oncol, 2008,19 (5) : 927- 934.
8Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizum- ab versus paclitaxel alone for metastatic breast cancer[ J]. N En- gl J Med, 2007, 357(26) :2666 -2676.
9Miles DW, Chan A, Romieu G, et al. Randomized, double- blind, placebo-controlled, phase m study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for pa- tients with locally recurrent or metastatic breast cancer (mBC) : AVADO[ J]. J Clin Oncol, 2008,26( 15 Suppl) : al011.
10Robert N J, Dieras V, Glaspy J, et al. RIBBON-1 : Randomized, double-blind, placebo-controlled, phase III trial of chemotherapywith or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [ J]. J Clin Oncol,2009,27( 15 Suppl) : a1005.
